Literature DB >> 11738314

Endogenous cannabinoids mediate hypotension after experimental myocardial infarction.

J A Wagner1, K Hu, J Bauersachs, J Karcher, M Wiesler, S K Goparaju, G Kunos, G Ertl.   

Abstract

OBJECTIVES: We sought to determine whether endocannabinoids influence hemodynamic variables in experimental models of acute myocardial infarction (MI).
BACKGROUND: Hypotension and cardiogenic shock are common complications in acute MI. Cannabinoids are strong vasodilators, and endocannabinoids are involved in hypotension in hemorrhagic and septic shock.
METHODS: The early effect of left coronary artery ligation on hemodynamic variables was measured in rats pretreated with the selective cannabinoid(1) receptor (CB(1)) antagonist SR141716A (herein referred to as SR, 6.45 micromol/kg body weight intravenously) or vehicle. Endocannabinoids produced in monocytes and platelets were quantified by liquid chromatography/mass spectrometry (LC/MS), and their effects on blood pressure and vascular reactivity were determined.
RESULTS: After MI, mean arterial pressure (MAP) dropped from 126 +/- 2 mm Hg to 76 +/- 3 mm Hg in control rats, whereas the decline in blood pressure was smaller (from 121 +/- 3 mm Hg to 108 +/- 7 mm Hg, p < 0.01) in rats pretreated with SR. SR increased the tachycardia that follows MI (change [Delta] in heart rate [HR] = 107 +/- 21 beats/min vs. 49 +/- 9 beats/min in control rats, p < 0.05). The MI sizes were the same in control rats and SR-treated rats. Circulating monocytes and platelets isolated 30 min after MI only decreased MAP when injected into untreated rats (DeltaMAP = -20 +/- 5 mm Hg), but not in SR-pretreated rats. The endocannabinoids anandamide and 2-arachidonyl glycerol were detected in monocytes and platelets isolated after MI, but not in cells from sham rats. Survival rates at 2 h after MI were 70% for control rats and 36% for SR-treated rats (p < 0.05). Endothelium-dependent arterial relaxation was attenuated in SR-treated rats (maximal relaxation: 44 +/- 3% [p < 0.01] vs. 70 +/- 3% in control rats) and further depressed by SR treatment (24 +/- 5%, p < 0.01 vs. MI placebo).
CONCLUSIONS: Cannabinoids generated in monocytes and platelets contribute to hypotension in acute MI. Cannabinoid(1) receptor blockade restores MAP but increases 2-h mortality, possibly by impairing endothelial function.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11738314     DOI: 10.1016/s0735-1097(01)01671-0

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  45 in total

1.  Endocannabinoids as mediators in the heart: a potential target for therapy of remodelling after myocardial infarction?

Authors:  C Robin Hiley; William R Ford
Journal:  Br J Pharmacol       Date:  2003-04       Impact factor: 8.739

2.  Presynaptic cannabinoid CB(1) receptors are involved in the inhibition of the neurogenic vasopressor response during septic shock in pithed rats.

Authors:  Grzegorz Godlewski; Barbara Malinowska; Eberhard Schlicker
Journal:  Br J Pharmacol       Date:  2004-05-24       Impact factor: 8.739

3.  Cannabinoid antagonist SR-141716 inhibits endotoxic hypotension by a cardiac mechanism not involving CB1 or CB2 receptors.

Authors:  Sándor Bátkai; Pál Pacher; Zoltán Járai; Jens A Wagner; George Kunos
Journal:  Am J Physiol Heart Circ Physiol       Date:  2004-04-01       Impact factor: 4.733

Review 4.  Endocannabinoids in cerebrovascular regulation.

Authors:  Zoltán Benyó; Éva Ruisanchez; Miriam Leszl-Ishiguro; Péter Sándor; Pál Pacher
Journal:  Am J Physiol Heart Circ Physiol       Date:  2016-01-29       Impact factor: 4.733

5.  Pharmacological inhibition of CB1 cannabinoid receptor protects against doxorubicin-induced cardiotoxicity.

Authors:  Partha Mukhopadhyay; Sándor Bátkai; Mohanraj Rajesh; Nora Czifra; Judith Harvey-White; György Haskó; Zsuzsanna Zsengeller; Norma P Gerard; Lucas Liaudet; George Kunos; Pál Pacher
Journal:  J Am Coll Cardiol       Date:  2007-07-23       Impact factor: 24.094

Review 6.  The therapeutic potential of drugs that target cannabinoid receptors or modulate the tissue levels or actions of endocannabinoids.

Authors:  Roger G Pertwee
Journal:  AAPS J       Date:  2005-10-24       Impact factor: 4.009

Review 7.  Endocannabinoids and cannabinoid receptors in ischaemia-reperfusion injury and preconditioning.

Authors:  P Pacher; G Haskó
Journal:  Br J Pharmacol       Date:  2007-11-19       Impact factor: 8.739

Review 8.  CB1 cannabinoid receptor inhibition: promising approach for heart failure?

Authors:  Partha Mukhopadhyay; Rajesh Mohanraj; Sándor Bátkai; Pál Pacher
Journal:  Congest Heart Fail       Date:  2008 Nov-Dec

9.  Circulating endocannabinoid concentrations during orthostatic stress.

Authors:  Christoph Schroeder; Sandor Batkai; Stefan Engeli; Jens Tank; André Diedrich; Friedrich C Luft; Jens Jordan
Journal:  Clin Auton Res       Date:  2009-12       Impact factor: 4.435

Review 10.  Cardiovascular effects of marijuana and synthetic cannabinoids: the good, the bad, and the ugly.

Authors:  Pal Pacher; Sabine Steffens; György Haskó; Thomas H Schindler; George Kunos
Journal:  Nat Rev Cardiol       Date:  2017-09-14       Impact factor: 32.419

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.